Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Xenon Pharmaceuticals to Present at Stifel 2022 CNS Days
04:01pm, Tuesday, 22'nd Mar 2022
BURNABY, British Columbia, March 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate
Biotech Sector Snapshot: Bleak Start To The Year, Catalyst Filled Q2 Awaits (NASDAQ:XENE)
12:06am, Sunday, 13'th Mar 2022 Seeking Alpha
In the past month, XBI is down 9% vs -6% for Nasdaq and -4% for SPY. YTD picture is even more bleak (-24% vs -18% & -11%).
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
10:25pm, Tuesday, 01'st Mar 2022 Zacks Investment Research
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -21.28% and 11.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto
Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q4 2021 Results - Earnings Call Transcript
10:24pm, Tuesday, 01'st Mar 2022
Xenon Pharmaceuticals Inc. (XENE) CEO Ian Mortimer on Q4 2021 Results - Earnings Call Transcript
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
09:01pm, Tuesday, 01'st Mar 2022 GlobeNewswire Inc.
Conference Call at 4:30 pm ET Today Conference Call at 4:30 pm ET Today
Xenon Pharmaceuticals Reports 2021 Financial Results and Provides Corporate Update
09:01pm, Tuesday, 01'st Mar 2022 GlobeNewswire
Conference Call at 4:30 pm ET Today Conference Call at 4:30 pm ET Today
Xenon Pharmaceuticals (XENE) Reports Q4 Loss, Lags Revenue Estimates
07:10pm, Tuesday, 01'st Mar 2022
Xenon Pharmaceuticals (XENE) delivered earnings and revenue surprises of -21.28% and 11.02%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto
Tabula Rasa Healthcare (TRHC) Reports Q4 Loss, Tops Revenue Estimates
01:10am, Friday, 25'th Feb 2022 Zacks Investment Research
Tabula Rasa Healthcare (TRHC) delivered earnings and revenue surprises of -28.57% and 0.76%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the sto
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update
09:01pm, Tuesday, 22'nd Feb 2022 GlobeNewswire Inc.
BURNABY, British Columbia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial res
Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Year-End 2021 Financial Results and Provide Corporate Update
04:01pm, Tuesday, 22'nd Feb 2022
BURNABY, British Columbia, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its financial resul
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
01:15pm, Wednesday, 16'th Feb 2022 Zacks Investment Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
09:01pm, Monday, 14'th Feb 2022 GlobeNewswire Inc.
BURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one
Xenon Pharmaceuticals to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
04:01pm, Monday, 14'th Feb 2022
BURNABY, British Columbia, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced its participation in one-on-one in
Xenon draws buyout speculation after Zogenix deal
03:51pm, Wednesday, 19'th Jan 2022 Seeking Alpha
Dealreporter flags Xenon Pharmaceuticals <> as a potential acquisition target following the agreement between Zogenix <> and UCB under which the Belgian drugmaker offered
Xenon passes regulatory mark to receive $15M from Neurocrine Biosciences
01:22pm, Wednesday, 12'th Jan 2022 Seeking Alpha
Xenon Pharmaceuticals (XENE) reaches regulatory milestone to receive a payment of $15M from Neurocrine Biosciences (NBIX) under its collaboration to develop treatments for epilepsy. It
